Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇫🇮FI · Medicine#112500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 Weekly cadence·26 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇫🇮100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel
Jun 17, 2026
Unknown duration
p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór
May 7, 2026
Unknown duration
Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
Feb 9, 2026
46m 58s
Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate
Dec 2, 2025
55m 14s
Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD
Nov 3, 2025
35m 42s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/17/26 | Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel | In this episode, host Dr Charles de Bock delves into groundbreaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in MDS with Dr Manja Wobus and Dr Katja Sockel. Join us as we unpack the mechanisms, animal studies, and future clinical prospects for this promising therapy.Read the accompanying article published in HemaSphere https://bit.ly/3OjuuiSi4MDS, EHA's Specialized Working Group information https://hsphere.pub/5d4 | — | ||||||
| 5/7/26 | p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór | Discover the latest insights into the multifaceted role of p53 in normal hematopoiesis and its critical involvement in myeloproliferative neoplasms (MPNs). This episode features Dr. Isabelle Plo and Dr. Barbara Monte-Mór sharing their expertise on TP53 mutations, molecular mechanisms driving leukemic transformation, and emerging therapeutic strategies targeting p53.Article: https://bit.ly/4sZbo01Comments, Suggestions or Feedback? Please take a few minutes and let us know: https://wkf.ms/4pDYjYb | — | ||||||
| 2/9/26 | Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood✨ | immunotherapyB-cell ALL+3 | Dr Matthew Greenwood | blinatumomabmenin inhibitors+3 | — | blinatumomabimmunotherapy+5 | — | 46m 58s | |
| 12/2/25 | Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate✨ | sickle cell diseasehealth inequalities+3 | Dr Stephen HibbsDr Paul Telfer+1 | HemaSphere JournalNICE (National Institute for Health and Care Excellence)+1 | — | sickle cell therapieshealth inequalities+3 | — | 55m 14s | |
| 11/3/25 | Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD✨ | acute leukemiaprecision medicine+3 | Dr. Anikó Sijs-SzabóRoger Mulet Lázaro, PhD | HemaSphere | — | leukemiatranscriptomics+5 | — | 35m 42s | |
| 10/1/25 | EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski✨ | CAR-T therapytoxicities+3 | Dr Kai Rejeski | HemaSphereEHA+1 | — | CAR-T therapytoxicities+5 | — | 40m 58s | |
| 9/1/25 | Tackling NUP98 Rearranged AML in Pediatric Oncology - Prof Michel Zwaan, Prof Olaf Heidenreich✨ | NUP98 rearranged AMLpediatric oncology+3 | Prof Michel ZwaanProf Olaf Heidenreich | HemaSphereThe MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML | — | NUP98AML+5 | — | 41m 07s | |
| 7/29/25 | Part 2 - Metabolism in hematology - Ep 3.4✨ | metabolismhematology+4 | Prof Dr Petya ApostolovaDr Jörg Büscher | HemaSphereHemaSphere Journal+1 | — | metabolismhematology+5 | — | 28m 52s | |
| 7/29/25 | Part 1 - Metabolism in hematology - Ep 3.4✨ | metabolismhematology+3 | Dr Jörg BüscherProf Dr Petya Apostolova | HemaSphereHemaSphere Journal | — | metabolismhematology+5 | — | 29m 51s | |
| 7/2/25 | Machine learning for AML-MRD - Ep 3.3✨ | machine learningacute myeloid leukemia+4 | Tim Mocking, PhD | HemaSphere JournalApplications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia | — | machine learningacute myeloid leukemia+5 | — | 29m 24s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/3/25 | 2 of 2: Navigating Neutropenia: New Guidelines Explained - Ep 3.2✨ | neutropeniatreatment guidelines+3 | Dr. Francesca FioreddaDr. Eleni Papadaki | European Hematology AssociationEuNet-INNOCHRON COST Action+2 | — | neutropeniatreatment guidelines+3 | — | 28m 05s | |
| 5/5/25 | Single‐cell DNA and surface protein - Ep 3.1✨ | acute lymphoblastic leukemiasingle cell sequencing+5 | Jan CoolsHeidi Segers+1 | HemaSphereHemaSphere Journal | — | acute lymphoblastic leukemiasingle cell DNA+5 | — | 34m 17s | |
| 4/2/25 | Two distinct fetal-type signatures characterize JMML - Ep 2.8 | In this episode of the HemaSphere podcast, host Charles de Bock engages with Professor Hélène Cavé and Dr. Marion Strullu to discuss their recent study on juvenile myelomonocytic leukemia (JMML). They delve into the complexities of diagnosing JMML, the genetic mutations associated with the disease, and the prognostic factors that influence patient outcomes. The conversation explores the intriguing biology of JMML, including the role of transcriptional signatures and methylation patterns, as well as the challenges faced in sample collection. The episode concludes with insights into future research directions in understanding JMML. "Two distinct fetal-type signatures characterize JMML" is on our website and all major podcast platforms (Spotify, Apple Podcast + more) and YouTube. Listen and enjoy casual,insightful discussions about #hematology research. You've read the paper, now hear the story.You can find the referenced article, in full and open access, here on the HemaSphere website. | — | ||||||
| 2/5/25 | Revolutionizing Pediatric Cancer Research with PDXs - Ep 2.7 | In this episode of the HemaSphere podcast, host Dr Charles de Bock discusses the critical role of mouse models in understanding leukemogenesis and hematopoiesis with Prof Richard Lock. They explore the significance of patient-derived xenografts (PDXs) in preclinical testing, the challenges faced in generating PDXs for acute myeloid leukemia (AML), and the importance of molecular characterization. The conversation also covers the objective response criteria in drug testing, the innovative single mouse trial approach, and the future of immunotherapy testing in PDX models. Revolutionizing Pediatric Cancer Research with PDXs is on our website and all major podcast platforms (Spotify, Apple Podcast, and more). Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphobloastic leukemia, in full and open access here on the HemaSphere website URLs mentioned in the recording: 15:09 PedcBioPortal 31:13 The Jackson Laboratory - Mouse Models | — | ||||||
| 1/7/25 | High 5hmC predicts worse OS - Ep 2.6 | In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.“High 5hmC predicts worse OS” is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube.Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, in full and open access, here on the HemaSphere website. | — | ||||||
| 11/27/24 | Informed consent is almost impossible - Ep 2.5 | This podcast episode delves into the complexities of informed consent in healthcare, particularly in the context of hematology. The discussion with host Dr Charles de Bock features insights from Dr Stephen Hibbs and Dr Louise Caldwell, authors of the HemaTopics "Informed consent is almost impossible” and guest Mark Dawson, a patient family member, exploring the emotional, legal, and ethical dimensions of consent. Key themes include the variability of consent across jurisdictions, the impact of time pressures on communication, and the importance of trust in the clinician-patient relationship. The conversation also addresses the challenges posed by genetic testing and the need for ongoing discussions about consent throughout a patient's treatment journey.“Informed consent is almost impossible”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research. Hear the stories behind the papers. You can find the referenced article, in full and open access, on the HemaSphere website.Publications mentioned in this podcast: The Immortal Life of Henrietta Lacks, by Rebecca SklootThe Logic of Care: Health and the Problem of Patient Choice, by Annemarie Mol | — | ||||||
| 10/25/24 | Best of Pediatric Hematology from EHA2024 - Ep 2.4 | In the latest episode, Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan. “Best of Pediatric Hematology from EHA2024”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research. We are pleased to offer HemaSphere’s full listing of publications about pediatric hematology, now in a dedicated collection. This online collection will be added to monthly. You can find the referenced article, in full and open access, on the HemaSphere website. | — | ||||||
| 10/3/24 | NOTCH1 fusions in T‐LBL - Ep 2.3 | Authors of this recent HemaSphere published paper discovered a high-risk subgroup of pediatric T-LBL, defined by NOTCH1 gene fusions. This finding will have an important impact on newly diagnosed children with T-LBL globally, listen to two of the co-authors, Dr Jan Loeffen and Professor Roland Kuipers discuss their findings with Dr Charles de Bock, how they discovered them, and dreams of future developments in this HemaSphere podcast episode.NOTCH1 fusions in T‐LBL, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) including YouTube Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, in full and open access, here on the HemaSphere website. | — | ||||||
| 7/29/24 | A transcriptional cofactor‐mediated dependency module - Ep 2.2 | In this newest podcast episode, Dr Charles de Bock hosts Dr Thomas Mercher and Dr Alexandre Fagnan. This episode is based on their recent paper, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program”, highlighting ETO2 activated gene transcription and how this affects erythroleukemia. The discussion traces the journey from part of Dr Fagnan’s PhD project (2022 EHA Junior Grant awardee), the findings in the paper and what may lie beyond. This episode is also available on our YouTube channel .Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program” in full and open access, here on the HemaSphere website. | — | ||||||
| 7/2/24 | Unraveling the secrets of thrombopoiesis - Ep 2.1 | Welcome to Season 2 of our podcast! In this episode, Dr. Francesca Vinchi interviews Professor Alessandra Balduini about thrombopoiesis. They explore Prof. Balduini's journey into research, her intuition that led to silk scaffolding, and her hopes on future results."Unraveling the secrets of thrombopoiesis", is on our website and all major podcast platforms (Spotify, Apple Podcast, YouTube, etc). Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, "Targeting Bone Marrow Mechanosensation in Myelofibrosis." in full and open access, here on the HemaSphere website. | — | ||||||
| 12/6/23 | What’s so Great About the P-value? A Statistician’s Point of View - Ep 1.8 | Dr Stephen Hibbs invites HemaSphere Associate Editor Prof Robert K Hills to discuss statistics in scientific writing in an entertaining and informative episode: What’s so Great About the P-value? A Statistician’s Point of View. This discussion covers the overlap of statistics and hematology with themes like the importance of P value and the use of statistics in clinical trials.What’s so Great About the P-value? A Statistician’s Point of View, is on our website , all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube. Listen and enjoy casual, insightful discussions about #hematology research. HemaSphere articles are always fully open access. Recent HemaSphere articles you may find interesting: Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Merryman R, Michaud L, Redd R, et al. Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.Palmi C, Bresolin S, Junk S, et al. | — | ||||||
| 11/2/23 | This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies - Ep 1.7 | Dr Stephen Hibbs invites Dr Joseph Taylor to a discussion based on Dr Hibbs popular HemaTopics article, This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies. The conversation ranges from the type of training providers receive, how to talk to patients about these bone marrow biopsies, and some of the outstanding questions about bone marrow biopsies and the patient experience. This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies, is on our website, all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube. You can find the referenced article, in full and open access, on the HemaSphere website.Listen and enjoy casual, insightful discussions about #hematology research. HemaTopics are HemaSphere publications written by our Scientific Editors, focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. | — | ||||||
| 10/4/23 | 1 of 2: The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children - Ep 1.6 | Though many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action, discuss with host Dr Stephen Hibbs the challenges and outcomes in creating a guideline for diagnosis and managing neutropenia in adults and children. Read the referenced article on the HemaSphere website and watch on YouTube. | — | ||||||
| 9/6/23 | Part 2 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.5 | POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehensive Diagnosis and Management of POEMS Syndrome offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this second of two episodes, why multidisciplinary collaboration is essential. Catch up with Part 1 here. Read the referenced article in HemaSphere, and also watch the videos onYouTube: Part 1 https://youtu.be/TE-t-rPztJw Part 2 https://youtu.be/hBE7KShFRhI | — | ||||||
| 9/6/23 | Part 1 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.4 | POEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehensive Diagnosis and Management of POEMS Syndrome, offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this first of 2 episodes, why multidisciplinary collaboration is essential. Continue with Part 2 here. This podcast is also available on YouTube: Part 1 and Part 2 | — | ||||||
Showing 25 of 28
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.